Know Cancer

forgot password

A Phase 2a Open-Label Clinical Trial Evaluating Efficacy & Safety of CPI-613 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML), and in Patients With Myelodysplastic Syndrome (MDS) Who Failed Hypomethylating Agents

Phase 2
18 Years
Not Enrolling
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)

Thank you

Trial Information

A Phase 2a Open-Label Clinical Trial Evaluating Efficacy & Safety of CPI-613 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML), and in Patients With Myelodysplastic Syndrome (MDS) Who Failed Hypomethylating Agents

A new therapy for AML is necessary because, although there are several treatment options for
patients with AML, these treatments are very toxic and not available to all AML patients or
only useful for acute promyelocytic leukemia (APL). Also, there is essentially no treatment
for patients with refractory or relapsed AML outside of bone marrow transplant.
Accordingly, there is a great medical need for a safe and effective therapy for AML,
especially refractory and relapsed AML. Also, although hypomethylating agents have been
found to be effective against MDS, these agents are toxic. Furthermore, after relapsing from
a hypomethylating agent, there is no treatment for this disease.

A nearly completed clinical trial of CPI-613 (Cornerstone Study# CL-CPI-613-009 or Wake
Forest Study# CCCWFU 29109, under IND# 107,800) shows that CPI-613 is well tolerated at
doses as high as 3,000 mg/m2. Results from this nearly completed trial also suggest that
CPI- 613 may be effective against refractory and relapsed AML, as well as against MDS that
is relapsed from a hypomethylating agent. Therefore, CPI-613 may be a suitable treatment
option for refractory/relapsed AML and MDS relapsed from a hypomethylating agent. The
promising preliminary efficacy data from Study# CL-CPI-613-009 (Wake Forest Study# CCCWFU
29109, under IND# 107,800) is the basis on which Cornerstone is conducting the current Phase
2a trial to further assess the efficacy of CPI-613 against these diseases.

Inclusion Criteria:

- Have either documented refractory or relapsed AML, or documented MDS of any risk
group that has failed a hypomethylating agent (such as decitabine [Vidaza] and
azacitidine [AZA]). (Therapy failure with a hypomethylating agent is defined as
patients who have been sufficiently treated with hypomethylating agents without
response in the opinion of the treating physician, or whose disease has progressed or
relapsed while on a hypomethylating agent.) Has never been treated with CPI-613.

- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.

- Expected survival >2 months.

- 18 years of age and older of both genders.

- Women of child-bearing potential (i.e., women who are pre-menopausal or not
surgically sterile) must use accepted contraceptive methods (abstinence, intrauterine
device [IUD], oral contraceptive, or double barrier device) during the study, and
must have a negative serum or urine pregnancy test within 1 week prior to treatment

- Fertile men must practice effective contraceptive methods during the study, unless
documentation of infertility exists.

- No radiotherapy, surgery or hormonal therapy for any kind of within 2 weeks prior to
participating in this study. Patients must have fully recovered from the acute
toxicities of any prior treatment with any anti-cancer drugs (including
hypomethylating agents in MDS patients), radiotherapy or other anti-cancer modalities
(i.e., returned to baseline status as noted before most recent treatment) for any
tumors. Patients with persisting, stable chronic toxicities from such prior treatment
≤Grade 1 are eligible, but must be documented as such.

- Recombinant erythropoietin or G-CSF is not allowed, since CPI-613 does not induce

- No evidence of active or serious infection of any kind within the past month. No
systemic fungal, bacterial, viral or other infection not controlled, defined as
exhibiting ongoing signs/symptoms related to the infection and without improvement,
despite appropriate antibiotics or other treatment.

- Signed informed consent form.

Exclusion Criteria:

- Serious medical illness, such as significant cardiac disease (e.g. symptomatic
congestive heart failure, unstable angina pectoris, myocardial infarction within the
past 6 months, uncontrolled cardiac arrhythmia, or New York Heart Association Class
III or IV), or severe debilitating pulmonary disease, that would potentially increase
patients' risk for toxicity.

- Active heart disease including myocardial infarction within the previous 6 months,
symptomatic coronary artery disease, abnormal ECG, or symptomatic congestive heart

- Any active uncontrolled bleeding, or any patients with a bleeding diathesis (e.g.,
active peptic ulcer disease).

- Dyspnea with minimal to moderate exertion. Patients with large pleural, pericardial,
or peritoneal effusions.

- Evidence of active infection, or serious infection within the past month.

- Patients with active central nervous system (CNS) or epidural solid or hematologic

- Patients receiving any standard or investigational therapy for any tumor indication
within the past 2 weeks, or any investigational agent for any indication within the
past 4 weeks, prior to the study.

- Patients who have received immunotherapy of any type for any indications within the
past 4 weeks prior to the study.

- Ongoing oral corticosteroids are not permitted. However, topical and inhaled
corticosteroids are permitted, and prophylactic steroids are allowed for transfusion

- Life expectancy less than 2 months.

- Pregnant women, or women of child-bearing potential not using reliable means of

- Lactating females.

- Fertile men unwilling to practice contraceptive methods during the study period.

- Unwillingness or inability to follow protocol requirements.

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Overall Survival (OS)

Outcome Time Frame:

Monitored until participants passed away, for an expected average of 6 months.

Safety Issue:


Principal Investigator

King C Lee, Ph.D.

Investigator Role:

Study Director

Investigator Affiliation:

Cornerstone Pharmaceuticals, Inc.


United States: Food and Drug Administration

Study ID:




Start Date:

May 2012

Completion Date:

December 2013

Related Keywords:

  • Acute Myeloid Leukemia (AML)
  • Myelodysplastic Syndrome (MDS)
  • acute myeloid leukemia
  • myelodysplastic syndrome
  • refractory
  • relapsed
  • hypomethylating agents
  • Leukemia
  • Leukemia, Myeloid, Acute
  • Leukemia, Myeloid
  • Myelodysplastic Syndromes
  • Preleukemia



Cornerstone Pharmaceuticals, Inc Cranbury, New Jersey  08512